Vobarilizumab

Vobarilizumab (INN; development code ALX0061) is a humanized monoclonal antibody designed for the treatment of inflammatory autoimmune diseases.[1][2]

Vobarilizumab
Monoclonal antibody
TypeSingle-chain variable fragment
SourceHumanized
TargetIL6R
Clinical data
Other namesALX0061
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC1118H1757N315O364S8
Molar mass25691.68 g·mol−1

This drug was developed by Ablynx NV.

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.